501892-99-5

Usage

Uses

Used in Pharmaceutical Synthesis:
3-METHYLBENZOFURAN-5-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structure and reactivity. Its presence in these compounds can contribute to their therapeutic effects and medicinal value.
Used in Organic Synthesis:
In the field of organic synthesis, 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID is used as a building block for creating a wide range of organic compounds. Its aromatic nature and functional groups make it a valuable component in the development of new chemical entities with potential applications in various industries.
Used in Fragrance Industry:
3-METHYLBENZOFURAN-5-CARBOXYLIC ACID is used as a fragrance ingredient in the perfumery and cosmetics industry. Its aromatic properties allow it to contribute to the creation of unique and complex scents for various products.
Used in Research and Development:
In academic and industrial research settings, 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID is used as a starting material for the development of new chemical compounds and the study of its reactivity and properties. This helps in advancing the understanding of organic chemistry and the discovery of new applications for 3-METHYLBENZOFURAN-5-CARBOXYLIC ACID.

InChI:InChI=1/C10H8O3/c1-6-5-13-9-3-2-7(10(11)12)4-8(6)9/h2-5H,1H3,(H,11,12)

Upstream product

• 501892-98-4 methyl 3-methylbenzofuran-5-carboxylate 
• 15126-06-4 methyl 3-iodo-4-hydroxybenzoate 
• 501892-97-3 methyl 4-(allyloxy)-3-iodobenzoate 
• 57009-12-8 methyl 3-acetyl-4-hydroxybenzoate 
• 96-32-2 bromoacetic acid methyl ester 
• 16357-40-7 3-acetyl-4-hydroxybenzoic acid 

Downstream Products

• 1379278-90-6 3-chlorobenzofuran-5-carboxylaic acid 

Relevant academic research and scientific papers

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease

The invention provides compounds of Formula I: which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which α7 nicotinic acetylcholine receptors (nAChRs) are known to be involved.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.